The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

while 22% were marked up by more than 1,000%," the report states. "For the pulmonary hypertension drug tadalafil (generic ...

Opella reaches study milestone for CialisParis, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and ...

But this medication is also used to treat symptoms of BPH (benign prostatic hyperplasia) under the brand name Adcirca®. And it’s sometimes prescribed for pulmonary arterial hypertension (PAH ...

Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis ...

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold ...

Other products, including Orenitram and Unituxin, also saw solid revenue growth, while Remodulin and Adcirca experienced ... transition regarding oral-only drugs into Medicare Part B, which ...